Treatment & Diagnostics

With our spin-out diagnostic partner Myconostica (winner of the North West BioNow Biomedical Project of the Year Award), we have developed clinically-validated and CE-marked detection of Aspergillus and Pneumocystis DNA from clinical samples. We have used the extracted DNA to detect antifungal resistance mutations directly, even in culture negative samples, and this is being clinically implemented for the first time for a fungus. We have identified novel anti-fungal drugs, one of which is in Phase 2.